BioSpace News Archive

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients.

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host an investor conference call and webcast on Monday, May 17, 2021 at 9:00 a.m. EST to discuss financial results for the quarter ending March 31, 2021 and provide a corporate update.

Building on their existing partnership to promote safer ultrasound-guided regional anesthesia, Konica Minolta Healthcare Americas, Inc. and Medovate, will showcase their combined solution and sponsor educational and training sessions at the American Society of Regional Anesthesia and Pain Medicine (ASRA) 46th Annual Meeting. Mercury Medical,

Irish based cell engineering company, Avectas today announces the publication of ‘A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications’ in leading international cell and gene therapy publication, Cytotherapy.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 2021 Jefferies Virtual Healthcare Conference, June 1-4, 2021 .

Atlas Venture, a leading early stage venture capital firm, announced that Samantha Truex is joining the firm as a venture partner.

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, reported financial results for the first quarter ended March 31, 2021.

Study will evaluate maveropepimut-S (formerly known as DPX-Survivac) with an aromatase inhibitor, with/without radiotherapy or cyclophosphamide prior to surgery

The program recognizes community leaders whose work exemplifies best practices in supporting people with lung cancer in at-risk communities

Preclinical data provide quantitative evidence of miRARE’s ability to exhibit genotype-dependent regulation of MECP2 gene expression across different brain regions in both wild type and knockout mouse models of Rett syndrome